Skip to main content

Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.

Publication ,  Journal Article
Damento, G; Kavoussi, SC; Materin, MA; Salomão, DR; Quiram, PA; Balasubramaniam, S; Pulido, JS
Published in: Mayo Clin Proc
November 2014

OBJECTIVE: To describe the progression of uveal melanocytic lesions to melanomas after initiation of tumor necrosis factor-α (TNF-α) inhibitors. PATIENTS AND METHODS: We report 3 cases of uveal melanoma occurring after treatment with TNF-α inhibitors, 2 from Mayo Clinic and 1 from Yale University. The study took place from February 27, 2009, through July 15, 2013. RESULTS: Two women and one man with inflammatory disease who received TNF-α inhibitors had subsequent development of uveal melanomas. The 2 women had inflammatory bowel disease and had been followed up for melanocytic tumors that grew markedly within 1 year after beginning treatment with TNF-α inhibitors to the point of requiring treatment. One had histologic confirmation of the melanoma. The male patient had rheumatoid arthritis that was being treated with TNF-α inhibitors. Serial ultrasonography was performed to monitor bilateral diffuse scleritis, and within 16 months of initiation of TNF-α inhibitor therapy, a choroidal mass was detected that continued to grow over the next 3 months. The patient elected to have enucleation, which revealed uveal melanoma and thinning of the sclera from the previous scleritis. CONCLUSION: Our 3 cases of uveal melanocytic tumors occurring after the use of TNF-α inhibitors add to the growing literature suggesting a correlation between TNF-α inhibitors and the development of malignant neoplasms. Considering the association between cutaneous melanoma and TNF-α inhibitors, we recommend that patients have an eye examination before initiation of TNF-α inhibitors, and those with preexisting nevi should be followed up at regular intervals.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Mayo Clin Proc

DOI

EISSN

1942-5546

Publication Date

November 2014

Volume

89

Issue

11

Start / End Page

1481 / 1486

Location

England

Related Subject Headings

  • Uveal Neoplasms
  • Tumor Necrosis Factor-alpha
  • Middle Aged
  • Melanoma
  • Male
  • Inflammatory Bowel Diseases
  • Immune System
  • Humans
  • Female
  • Disease Progression
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Damento, G., Kavoussi, S. C., Materin, M. A., Salomão, D. R., Quiram, P. A., Balasubramaniam, S., & Pulido, J. S. (2014). Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin Proc, 89(11), 1481–1486. https://doi.org/10.1016/j.mayocp.2014.08.012
Damento, Gena, Shaheen C. Kavoussi, Miguel A. Materin, Diva R. Salomão, Polly A. Quiram, Saranya Balasubramaniam, and Jose S. Pulido. “Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.Mayo Clin Proc 89, no. 11 (November 2014): 1481–86. https://doi.org/10.1016/j.mayocp.2014.08.012.
Damento G, Kavoussi SC, Materin MA, Salomão DR, Quiram PA, Balasubramaniam S, et al. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2014 Nov;89(11):1481–6.
Damento, Gena, et al. “Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.Mayo Clin Proc, vol. 89, no. 11, Nov. 2014, pp. 1481–86. Pubmed, doi:10.1016/j.mayocp.2014.08.012.
Damento G, Kavoussi SC, Materin MA, Salomão DR, Quiram PA, Balasubramaniam S, Pulido JS. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors. Mayo Clin Proc. 2014 Nov;89(11):1481–1486.

Published In

Mayo Clin Proc

DOI

EISSN

1942-5546

Publication Date

November 2014

Volume

89

Issue

11

Start / End Page

1481 / 1486

Location

England

Related Subject Headings

  • Uveal Neoplasms
  • Tumor Necrosis Factor-alpha
  • Middle Aged
  • Melanoma
  • Male
  • Inflammatory Bowel Diseases
  • Immune System
  • Humans
  • Female
  • Disease Progression